Nav: Home

Antiretroviral drugs are not foolproof in preventing sexual transmission of HIV, says Pittsburgh-Rio de Janeiro study

August 14, 2000

Antiretroviral therapy for HIV patients can be a double-edged sword, according to University of Pittsburgh AIDS researchers and their Brazilian colleagues. Investigators showed that while the drugs can greatly reduce the amount of infectious HIV in semen (viral load), a substantial percentage of men may still be able to transmit the virus sexually. This is the first-ever study to simulate a clinical environment in looking at the effects of antiretroviral drugs on HIV concentration in semen.

The findings, made by researchers at the University of Pittsburgh Graduate School of Public Health (GSPH) and School of Medicine, and the Universidade Federal do Rio de Janeiro (Brazil), are published in the August 15 issue of the Annals of Internal Medicine.

"Our study is the first to show that, in a real-world setting, a substantial percentage of HIV-positive men have active, potentially infectious virus in their semen, even after six months of therapy," said Lee Harrison, M.D., associate professor of medicine and epidemiology, director of the Public Health Infections Diseases Lab at the University of Pittsburgh and senior author of the study.

Previous small, short-term studies have suggested that antiretroviral therapy reduces, but not completely eliminates, seminal viral load in HIV-infected men. But, because these earlier studies were not definitive for a number of reasons, scientists remained unsure whether the findings would translate into a larger community setting. The Pittsburgh-Rio de Janeiro study provides a clearer picture of just how resilient -- and potentially transmittable -- the AIDS virus is during therapy.

"Certainly, current drug regimens have been shown to reduce the likelihood of sexual transmission of HIV, and our study has provided additional evidence that these regimens are effective in reducing viral load in both the blood and semen of many men in our study," commented Paulo Barroso, M.D., Ph.D., assistant professor and head, Infectious Diseases Service, School of Medicine, Universidade Federal do Rio de Janeiro. "Nonetheless, a significant proportion of men who underwent therapy and subsequently felt well remained potentially infectious and therefore continue to pose a public health risk unless they monitor their sexual behavior carefully."

The study was conducted at the Hospital Universitário Clementino Fraga Filho in Rio de Janeiro from November 1996 through May 1998. Ninety-three HIV-infected male volunteers agreed to undergo antiretroviral therapy, with the decision to start, change or stop therapy left up to the volunteers and their personal physicians, thus simulating a clinical environment. All but two of the subjects were antiretroviral-naïve (had never been on antiretroviral therapy).

Eighty of the study subjects began with a double nucleoside reverse transcriptase inhibitor (NRTI) drug regimen. The best known NRTI is zidovudine (Retrovir), formerly known as AZT. NRTIs prevent the integration of HIV genes into the host cell's genome. Another type of drug, known as a protease inhibitor, was added to the regimen for 13 of the subjects. Protease inhibitors block the release of mature, infectious HIV particles from HIV-infected immune cells. By the end of the study, 19 subjects were using the triple-drug program, having changed drug regimens upon the advice of their own physicians.

After six months of therapy, there was a 66 percent reduction in the number of study subjects with detectable seminal HIV viral load. Of the 64 subjects who had detectable HIV in their semen before initiating therapy, 44 had undetectable levels after six months. Also, those volunteers who used the double nucleoside had a statistically significant reduction in seminal HIV viral load as measured at all follow-up visits one, two, three and six months after initiation of therapy.

"In spite of these impressive treatment outcomes, a third of the treated men had infectious virus in their semen after six months, including 13 percent of patients who were taking a protease-inhibitor-containing triple-drug regimen" said Dr. Barroso. "Thus, because there is no guarantee that HIV-infected individuals will not be infectious themselves, they should continue to practice safe sex and follow medication instructions to the letter."

In a landmark study conducted previously at the University of Pittsburgh's GSPH, investigators found infectious HIV in the semen of a small group of men who had received antiretroviral therapy and who were in various stages of disease. More recent work has shown that, even after HIV-infected patients underwent antiretroviral therapy, so-called HIV "provirus" remained integrated within the genome of cells in semen. Whether these patients are infectious or not, however, is not known.

"In general, it's safe to say that men who have a detectable viral load after six months on therapy have a high likelihood of carrying - and possibly sexually transmitting - infectious HIV," said Dr. Harrison. "We suspect that the seminal HIV in these men is drug resistant, although definitive studies examining this issue are still ongoing."

A further concern, according to Drs. Harrison and Barroso, is that treated men do not become complacent because they are on aggressive therapy. This study confirms the finding that infectious HIV may still lurk within their semen.
Lauren Ward
FAX: 412-624-3184

University of Pittsburgh Medical Center

Related Hiv Articles:

Defective HIV proviruses reduce effective immune system response, interfere with HIV cure
A new study finds defective HIV proviruses, long thought to be harmless, produce viral proteins and distract the immune system from killing intact proviruses needed to reduce the HIV reservoir and cure HIV.
1 in 7 people living with HIV in the EU/EEA are not aware of their HIV status
Almost 30,000 newly diagnosed HIV infections were reported by the 31 European Union and European Economic Area (EU/EEA) countries in 2015, according to data published today by ECDC and the WHO Regional Office for Europe.
Smoking may shorten the lifespan of people living with HIV more than HIV itself
A new study led by researchers at Massachusetts General Hospital finds that cigarette smoking substantially reduces the lifespan of people living with HIV in the US, potentially even more than HIV itself.
For smokers with HIV, smoking may now be more harmful than HIV itself
HIV-positive individuals who smoke cigarettes may be more likely to die from smoking-related disease than the infection itself, according to a new study published in the Journal of Infectious Diseases.
Patients diagnosed late with HIV infection are more likely to transmit HIV to others
An estimated 1.2 million people live with HIV in the United States, with nearly 13 percent being unaware of their infection.
The Lancet HIV: New HIV infections stagnating at 2.5 million a year worldwide
A major new analysis from the Global Burden of Disease 2015 study, published today in The Lancet HIV journal, reveals that although deaths from HIV/AIDS have been steadily declining from a peak in 2005, 2.5 million people worldwide became newly infected with HIV in 2015, a number that hasn't changed substantially in the past 10 years.
NIH scientists discover that defective HIV DNA can encode HIV-related proteins
Investigators from the National Institutes of Health have discovered that cells from HIV-infected people whose virus is suppressed with treatment harbor defective HIV DNA that can nevertheless be transcribed into a template for producing HIV-related proteins.
Study examines risk of HIV transmission from condomless sex with virologically suppressed HIV infection
Among nearly 900 serodifferent (one partner is HIV-positive, one is HIV-negative) heterosexual and men who have sex with men couples in which the HIV-positive partner was using suppressive antiretroviral therapy and who reported condomless sex, during a median follow-up of 1.3 years per couple, there were no documented cases of within-couple HIV transmission, according to a study appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue.
HIV vaccine design should adapt as HIV virus mutates
Researchers from UAB, Emory and Microsoft demonstrate that HIV has evolved to be pre-adapted to the immune response, worsening clinical outcomes in newly infected patients.
Charlie Sheen's HIV disclosure may reinvigorate awareness, prevention of HIV
Actor Charlie Sheen's public disclosure in November 2015 that he has the human immunodeficiency virus (HIV) corresponded with the greatest number of HIV-related Google searches ever recorded in the United States, according to an article published online by JAMA Internal Medicine.

Related Hiv Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...